Critical Analysis: Actuate Therapeutics (NASDAQ:ACTU) versus Psyence Biomedical (NASDAQ:PBM)

Actuate Therapeutics (NASDAQ:ACTU) and Psyence Biomedical (NASDAQ:PBM) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, valuation, risk and analyst recommendations.

Profitability

This table compares Actuate Therapeutics and Psyence Biomedical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Psyence Biomedical	N/A	N/A	N/A

Valuation & Earnings

This table compares Actuate Therapeutics and Psyence Biomedical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23 million	($0.97)	-1.05
Psyence Biomedical	N/A	N/A	-$6.94 million	$25.34	0.14

Actuate Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Actuate Therapeutics has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Psyence Biomedical has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings for Actuate Therapeutics and Psyence Biomedical, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1	0	3	0	2.50
Psyence Biomedical	1	0	0	0	1.00

Actuate Therapeutics presently has a consensus price target of $13.67, indicating a potential upside of 1,239.87%. Given Actuate Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Actuate Therapeutics is more favorable than Psyence Biomedical.

Insider & Institutional Ownership

77.4% of Psyence Biomedical shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Psyence Biomedical beats Actuate Therapeutics on 7 of the 11 factors compared between the two stocks.

About Actuate Therapeutics

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

About Psyence Biomedical

Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company’s lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.